World Health Organization Raises Warning Over Critical Scarcity of Obesity Injections
Fewer than a tenth of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, caution the WHO as it issues its first advice on the drugs.
Given more than one billion people worldwide currently classified as obese, it is urging more widespread and fairer availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The new guidance recognises that obesity is a long-term condition that can be managed with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are major hurdles to widespread access to the treatments that can aid individuals in losing significant weight, notes the organization.
Weight-Loss Drug Shortage
Even in the current most optimistic case, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of the global need, per the WHO.
The recommendation urges nations and manufacturers to increase availability, by strategies including patent sharing.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and boost feelings of fullness so people reduce food intake.
People commonly start to lose weight within a few weeks of beginning the regular doses.
Research suggests patients may see weight return within a year of stopping the treatment, when their normal hunger return.
Being carrying excess weight increases your likelihood for developing medical conditions, like type 2 diabetes, heart disease, stroke, and some malignancies.
Obesity concerns people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
